Triptorelin for Preserving Ovarian Function in Breast Cancer Patients
Chemotherapy-associated risk for early menopause was lower in women who received this gonadotropin-releasing hormone analogue.
Hereditary Breast and Ovarian Cancer: Earlier Onset with Each Generation
Women's Health Summary and Comment
Free
Younger age at diagnosis in subsequent generations of <$EMPH_O>BRCA<$EMPH_C> carriers bespeaks the importance of early breast screening.
Breast Cancer in Women Younger Than 25
Women's Health Summary and Comment
Free
Although cancer is uncommon in this age group, all breast masses should be evaluated.
By Andrew M. Kaunitz, MD
September 15, 2011
Covering:
Simmons PS et al., Obstet Gynecol 2011 Sep; 118:529
Occult Metastases in Breast Cancer Do Not Affect Survival Substantially
Routine detection of occult sentinel node and bone marrow micrometastases is not clinically indicated for early breast cancer.
By Abigail S. Caudle, MD, and Henry Mark Kuerer, MD, PhD, FACS
August 16, 2011
Covering:
Giuliano AE et al., JAMA 2011 Jul 27; 306:385
Merkow RP and Ko CY., JAMA 2011 Jul 27; 306:436
Revisiting High-Dose Chemotherapy for Breast Cancer
Meta-analyses show that overall survival was not prolonged in the adjuvant or metastatic setting.
By William J. Gradishar, MD
August 16, 2011
Covering:
Berry DA et al., J Clin Oncol 2011 Jul 18
Berry DA et al., J Clin Oncol 2011 Jul 18
Borges VF and Elias AD., J Clin Oncol 2011 Jul 18
Sorting Out the Value of Mammography
Women's Health Summary and Comment
Free
Analysis of paired European countries suggests screening has little effect on breast cancer mortality.
Is Computer-Assisted Detection Worthwhile for Mammographic Screening?
Women's Health Summary and Comment
Multicenter study results suggest that computer-assisted detection lowers specificity with little potential to improve breast cancer outcomes.
By Andrew M. Kaunitz, MD
August 11, 2011
Covering:
Fenton JJ et al., J Natl Cancer Inst 2011 Aug 3; 103:1152
Berry DA., J Natl Cancer Inst 2011 Aug 3; 103:1139
Mammograms: More New Screening Guidelines
Women's Health Clinical Practice Guideline Watch
Free
The American College of Obstetricians and Gynecologists now recommends annual screening beginning at age 40.
By Andrew M. Kaunitz, MD
July 28, 2011
Covering:
ACOG Committee on Practice Bulletins–Gynecology., Obstet Gynecol 2011 Aug; 118:372
Goserelin Does Not Preserve Ovarian Function During Chemotherapy
This luteinizing-hormone–releasing hormone agonist was of no benefit for young women receiving anthracycline-based adjuvant chemotherapy for breast cancer.
Mammography Screening and Breast Cancer Mortality: Long-Term Advantages
Women's Health Summary and Comment
Swedish data based on 3 decades of follow-up show major benefits of screening.
Lifestyle's Effects on Absolute Risk for Breast Cancer
Women's Health Summary and Comment
New model predicts the effects of modifying alcohol consumption, physical activity, and body-mass index.
By Andrew M. Kaunitz, MD
July 14, 2011
Covering:
Petracci E et al., J Natl Cancer Inst 2011 Jul 6; 103:1037
Helzlsouer KJ., J Natl Cancer Inst 2011 Jul 6; 103:992
Breast Cancer and OCs: Still Worried After All These Years?
Women's Health Summary and Comment
Free
Two studies confirm that oral contraceptives are not associated with breast cancer–specific or all-cause mortality.
Breast-Conserving Therapy vs. Mastectomy for Triple-Negative Breast Cancer
In women with T1-2N0 TNBC, risk for local regional recurrence was lower after lumpectomy plus radiotherapy than after modified radical mastectomy.
Landmark Biomarker Studies Are Likely to Overstate Findings
Cardiology Summary and Comment
Results of frequently cited studies often differ markedly from those of meta-analyses or studies in larger populations.
By JoAnne M. Foody, MD
July 6, 2011
Covering:
Ioannidis JPA and Panagiotou OA., JAMA 2011 Jun 1; 305:2200
Bossuyt PMM., JAMA 2011 Jun 1; 305:2229
Beta-Blockers as Breast Cancer Therapy?
Two studies suggest beneficial effects on breast cancer recurrence and survival, but many questions remain.
By William J. Gradishar, MD
June 28, 2011
Covering:
Melhem-Bertrandt A et al., J Clin Oncol 2011 May 31
Barron TI et al., J Clin Oncol 2011 May 31
Exemestane for Breast Cancer Prevention
General Medicine Summary and Comment
In a 3-year trial, this drug lowered breast cancer incidence in postmenopausal women.
By Allan S. Brett, MD
June 23, 2011
Covering:
Goss PE et al., N Engl J Med 2011 Jun 23; 364:2381
When Biology Bests Clinical Assumptions About Breast Cancer
Tumor biology is a critically important factor that must be integrated into the determination of prognosis.
By William J. Gradishar, MD
June 14, 2011
Covering:
Wo JY et al., J Clin Oncol 2011 May 23
Hernandez-Aya LF et al., J Clin Oncol 2011 May 23
Breast Density: A Marker of Tamoxifen's Preventive Benefit?
Tamoxifen-associated reductions in mammographic breast density predicted breast cancer risk reduction.
BMI and Efficacy of Endocrine Therapy for Premenopausal Breast Cancer
Women's Health Summary and Comment
Free
Efficacy of an aromatase inhibitor plus goserelin was compromised in patients with high body-mass index.
Characterizing Breast Cancers That Elude Mammographic Screening
Women's Health Summary and Comment
Free
Interval cancers have worse prognostic features than do those detected with routine screening.
Striking Back at Trastuzumab Resistance in Breast Cancer
A new strategy is directed at a convergence point for several HER2 signaling pathways.
Reasons Behind Rising Contralateral Prophylactic Mastectomy Rates
Factors related to treatment of index breast cancer influenced CPM choices.
Long-Term Outcomes of Ductal Carcinoma in Situ
Breast-conserving treatments for DCIS are associated with excellent prognoses.
Follow-Up for Women with Abnormal Mammograms
Rapid, accurate identification of women who have breast cancer — as well as those who do <$EMPH_O>not<$EMPH_C> — is essential.
By Mitchel Barry, MD, and Mary L. Gemignani, MD, MPH, FACS
April 14, 2011
My Mammogram Is Abnormal. What Now?
Women's Health Patient Information
Abnormal mammogram results can have many causes other than breast cancer; be sure to follow up as your clinician recommends.
